Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations
PARP inhibitors have transformed the management of advanced high-grade serous ovarian cancer. Despite the overwhelming success of PARP inhibition, particularly in BRCA-mutated ovarian cancer, several limitations and unanswered questions remain. With PARP inhibitors now being used in earlier treatmen...
Saved in:
| Published in | Gynecologic oncology Vol. 156; no. 2; pp. 488 - 497 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
01.02.2020
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0090-8258 1095-6859 1095-6859 |
| DOI | 10.1016/j.ygyno.2019.09.021 |
Cover
| Abstract | PARP inhibitors have transformed the management of advanced high-grade serous ovarian cancer. Despite the overwhelming success of PARP inhibition, particularly in BRCA-mutated ovarian cancer, several limitations and unanswered questions remain. With PARP inhibitors now being used in earlier treatment settings, the issue of both de novo and acquired resistance mechanisms and appropriate post-PARP management are pressing concerns. In addition, the population appropriate to target with PARP inhibitors and their use in patients without BRCA mutations is controversial and evolving. In this review we will discuss exciting PARP combinations and biologic rationale for the development and selection of PARP inhibitor combinations.
•PARP inhibitors (PARPi) have transformed the management of advanced ovarian cancer.•With increased PARPi use, the resistance to PARPi will become a increasing clinical concern.•Combinatorial approaches can overcome de novo and acquired resistance to PARPi by exploiting DDR mechanisms.•PARPi combinations can induce “BRCAness”, inhibit DNA repair, promote replication stress, or enhance immunomodulation.•Selection of the appropriate combination for the clinical context could overcome, or prevent, PARPi resistance. |
|---|---|
| AbstractList | PARP inhibitors have transformed the management of advanced high-grade serous ovarian cancer. Despite the overwhelming success of PARP inhibition, particularly in BRCA-mutated ovarian cancer, several limitations and unanswered questions remain. With PARP inhibitors now being used in earlier treatment settings, the issue of both de novo and acquired resistance mechanisms and appropriate post-PARP management are pressing concerns. In addition, the population appropriate to target with PARP inhibitors and their use in patients without BRCA mutations is controversial and evolving. In this review we will discuss exciting PARP combinations and biologic rationale for the development and selection of PARP inhibitor combinations. PARP inhibitors have transformed the management of advanced high-grade serous ovarian cancer. Despite the overwhelming success of PARP inhibition, particularly in BRCA-mutated ovarian cancer, several limitations and unanswered questions remain. With PARP inhibitors now being used in earlier treatment settings, the issue of both de novo and acquired resistance mechanisms and appropriate post-PARP management are pressing concerns. In addition, the population appropriate to target with PARP inhibitors and their use in patients without BRCA mutations is controversial and evolving. In this review we will discuss exciting PARP combinations and biologic rationale for the development and selection of PARP inhibitor combinations. •PARP inhibitors (PARPi) have transformed the management of advanced ovarian cancer.•With increased PARPi use, the resistance to PARPi will become a increasing clinical concern.•Combinatorial approaches can overcome de novo and acquired resistance to PARPi by exploiting DDR mechanisms.•PARPi combinations can induce “BRCAness”, inhibit DNA repair, promote replication stress, or enhance immunomodulation.•Selection of the appropriate combination for the clinical context could overcome, or prevent, PARPi resistance. PARP inhibitors have transformed the management of advanced high-grade serous ovarian cancer. Despite the overwhelming success of PARP inhibition, particularly in BRCA-mutated ovarian cancer, several limitations and unanswered questions remain. With PARP inhibitors now being used in earlier treatment settings, the issue of both de novo and acquired resistance mechanisms and appropriate post-PARP management are pressing concerns. In addition, the population appropriate to target with PARP inhibitors and their use in patients without BRCA mutations is controversial and evolving. In this review we will discuss exciting PARP combinations and biologic rationale for the development and selection of PARP inhibitor combinations.PARP inhibitors have transformed the management of advanced high-grade serous ovarian cancer. Despite the overwhelming success of PARP inhibition, particularly in BRCA-mutated ovarian cancer, several limitations and unanswered questions remain. With PARP inhibitors now being used in earlier treatment settings, the issue of both de novo and acquired resistance mechanisms and appropriate post-PARP management are pressing concerns. In addition, the population appropriate to target with PARP inhibitors and their use in patients without BRCA mutations is controversial and evolving. In this review we will discuss exciting PARP combinations and biologic rationale for the development and selection of PARP inhibitor combinations. AbstractPARP inhibitors have transformed the management of advanced high-grade serous ovarian cancer. Despite the overwhelming success of PARP inhibition, particularly in BRCA-mutated ovarian cancer, several limitations and unanswered questions remain. With PARP inhibitors now being used in earlier treatment settings, the issue of both de novo and acquired resistance mechanisms and appropriate post-PARP management are pressing concerns. In addition, the population appropriate to target with PARP inhibitors and their use in patients without BRCA mutations is controversial and evolving. In this review we will discuss exciting PARP combinations and biologic rationale for the development and selection of PARP inhibitor combinations. |
| Author | Liu, Joyce F. Konstantinopoulos, Panagiotis A. Matulonis, Ursula A. Veneris, Jennifer Taylor |
| Author_xml | – sequence: 1 givenname: Jennifer Taylor surname: Veneris fullname: Veneris, Jennifer Taylor email: Jennifer_Veneris@dfci.harvard.edu – sequence: 2 givenname: Ursula A. surname: Matulonis fullname: Matulonis, Ursula A. – sequence: 3 givenname: Joyce F. surname: Liu fullname: Liu, Joyce F. – sequence: 4 givenname: Panagiotis A. surname: Konstantinopoulos fullname: Konstantinopoulos, Panagiotis A. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31630846$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkl2L1DAUhoOsuB_6CwTJpTcdT5KmbRSFcfALFlx29Tq06eluxjYZk1Tpvzfj7N4s6MKBQHifNyfnPafkyHmHhDxnsGLAqlfb1XK9OL_iwNQKcnH2iJwwULKoGqmOyAmAgqLhsjkmpzFuAUAA40_IsWCVgKasTkjc3Hgfrbumv23EcXlNr3BEk_Y3F-vLC2rdje1s8oEaP3XWtcl6F2nydBf85BPS1iVbpHnKEjtNs0MaMO6yCCPtcPGup-8vN2s6zekAPyWPh3aM-Oz2PCPfP374tvlcnH_99GWzPi-MrOtUCBgUr1RXlqVshrripmGsqzvD5CAGNL0UKFXNRCM4a5reQGvKWuHQg8RKteKMvDz45k5_zhiTnmw0OI6tQz9HzQXUQlUcyix9cSuduwl7vQt2asOi7waVBeogMMHHGHDQxh6-k0JrR81A70PRW_03FL0PRUMuzjIr7rF39v-n3h4ozCP6ZTHoaCw6g70NOSDde_sA_-4eb0brrGnHH7hg3Po5uDx9zXTkGvTVfln2u8KUYLJUMhu8-bfBg8__AdYW0XU |
| CitedBy_id | crossref_primary_10_1097_MD_0000000000023040 crossref_primary_10_1111_bcp_15035 crossref_primary_10_1016_j_yao_2021_02_012 crossref_primary_10_5306_wjco_v12_i7_544 crossref_primary_10_1002_jcp_31015 crossref_primary_10_1016_j_dnarep_2021_103125 crossref_primary_10_1016_j_annonc_2020_06_004 crossref_primary_10_1016_j_ejcsup_2020_02_001 crossref_primary_10_1093_bmb_ldaa045 crossref_primary_10_1158_1078_0432_CCR_20_3322 crossref_primary_10_1080_13543776_2021_1886275 crossref_primary_10_1097_CAD_0000000000001160 crossref_primary_10_1200_EDBK_288015 crossref_primary_10_1007_s11912_024_01501_0 crossref_primary_10_1016_j_ygyno_2020_09_029 crossref_primary_10_3389_fgene_2022_886170 crossref_primary_10_1038_s43856_022_00142_3 crossref_primary_10_1093_neuonc_noab127 crossref_primary_10_1016_j_celrep_2023_113256 crossref_primary_10_3389_fimmu_2021_692360 crossref_primary_10_1080_14728214_2020_1773791 crossref_primary_10_1038_s43018_023_00617_9 crossref_primary_10_3389_fimmu_2023_1195476 crossref_primary_10_3390_life13051183 crossref_primary_10_1093_narcan_zcad043 crossref_primary_10_2478_fco_2021_0002 crossref_primary_10_2217_fon_2021_0899 crossref_primary_10_2174_0115748871260815231116060817 crossref_primary_10_1016_j_biopha_2020_110204 crossref_primary_10_1038_s41416_021_01664_8 crossref_primary_10_1038_s41416_022_01836_0 crossref_primary_10_2147_TACG_S245021 crossref_primary_10_1136_jitc_2020_001643 crossref_primary_10_3389_fgene_2022_931866 crossref_primary_10_3389_fonc_2024_1302850 crossref_primary_10_1186_s13000_023_01431_8 crossref_primary_10_1016_j_ebiom_2020_102988 crossref_primary_10_1158_0008_5472_CAN_21_0732 crossref_primary_10_3389_fonc_2023_1078388 crossref_primary_10_1016_j_ygyno_2024_11_006 crossref_primary_10_1080_14737140_2020_1820330 crossref_primary_10_1016_j_ygyno_2022_11_006 crossref_primary_10_1038_s41419_023_05580_y crossref_primary_10_3389_fonc_2022_888810 crossref_primary_10_3390_ijms22168924 crossref_primary_10_1016_j_drup_2021_100744 |
| Cites_doi | 10.1200/JCO.2009.23.2777 10.1200/JCO.2019.37.15_suppl.5523 10.1016/j.ctarc.2017.09.001 10.1056/NEJMoa1802905 10.18632/oncotarget.7277 10.1001/jamaoncol.2018.6258 10.1158/1078-0432.CCR-15-3069 10.1056/NEJMoa1903387 10.1016/S1470-2045(19)30029-4 10.1093/annonc/mdw672 10.1093/nar/gku088 10.1126/scitranslmed.aaf9246 10.1016/S1470-2045(16)30559-9 10.1016/j.ygyno.2015.03.042 10.1101/gad.290957.116 10.1016/S1470-2045(18)30009-3 10.1016/j.ygyno.2018.04.555 10.18632/oncotarget.22195 10.1016/S1470-2045(18)30905-7 10.1158/1078-0432.CCR-18-0204 10.1158/1078-0432.CCR-16-2273 10.1016/S1470-2045(11)70214-5 10.1093/annonc/mdw635 10.1016/j.cell.2006.11.042 10.1016/j.neo.2014.04.003 10.1016/S0959-8049(16)32607-7 10.1126/scitranslmed.aav4508 10.1126/scitranslmed.aal5148 10.1093/annonc/mdw133 10.1158/1535-7163.MCT-13-0683 10.1158/0008-5472.CAN-18-1003 10.1016/j.ygyno.2017.08.022 10.1016/j.ygyno.2018.11.017 10.1093/annonc/mdz012 10.1016/S1470-2045(18)30111-6 10.1074/jbc.M111.296475 10.1038/onc.2017.311 10.1056/NEJMoa1810858 10.1056/NEJMoa1506859 10.1158/1078-0432.CCR-17-1590 10.1016/S1470-2045(14)70391-2 10.1093/annonc/mdz135 10.1016/j.ygyno.2019.05.021 10.1158/2159-8290.CD-11-0336 10.1001/jamaoncol.2019.1048 10.1200/JCO.2018.36.15_suppl.5504 10.1371/journal.pone.0080023 10.1016/j.ejca.2013.05.020 10.1200/JCO.2018.36.15_suppl.2018 10.1126/scitranslmed.aal1645 10.1158/1078-0432.CCR-15-0652 10.1038/bjc.2011.555 10.1158/2159-8290.CD-15-0714 10.1016/j.celrep.2018.11.054 10.1007/s00280-013-2113-1 10.1158/0008-5472.CAN-05-2119 10.1093/annonc/mdx505 10.4161/cc.26062 10.1158/1078-0432.CCR-07-2238 10.1128/MCB.24.19.8504-8518.2004 10.1158/2159-8290.CD-11-0348 10.1097/IGC.0000000000000380 10.1200/JCO.2015.62.3397 |
| ContentType | Journal Article |
| Copyright | 2019 The Authors Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2019 The Authors – notice: Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved. |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.ygyno.2019.09.021 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1095-6859 |
| EndPage | 497 |
| ExternalDocumentID | 31630846 10_1016_j_ygyno_2019_09_021 S0090825819315495 1_s2_0_S0090825819315495 |
| Genre | Journal Article Review |
| GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29I 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFGL ADMUD ADNMO AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CAG COF CS3 DM4 DU5 EBS EFBJH EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HED HMK HMO HVGLF HZ~ IH2 IHE J1W K-O KOM L7B LG5 M29 M41 MO0 N9A O-L O9- OAUVE OQ. OZT P-8 P-9 P2P PC. PH~ Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SES SEW SPCBC SSH SSZ T5K UDS UHS UV1 WUQ X7M XPP Z5R ZGI ZMT ZU3 ZXP ~G- AACTN AFCTW AFKWA AJOXV AMFUW RIG 6I. AAFTH AAIAV ABLVK ABYKQ AHPSJ AJBFU EFLBG LCYCR AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 7X8 ACLOT ~HD |
| ID | FETCH-LOGICAL-c577t-30f9269b44458f762c811b7bc15f3fecd53e59713832188dc0ac479efd05e69a3 |
| IEDL.DBID | AIKHN |
| ISSN | 0090-8258 1095-6859 |
| IngestDate | Sun Sep 28 07:50:02 EDT 2025 Thu Apr 03 07:06:00 EDT 2025 Thu Apr 24 23:04:07 EDT 2025 Tue Jul 01 03:08:05 EDT 2025 Fri Feb 23 02:46:54 EST 2024 Tue Feb 25 20:12:37 EST 2025 Tue Aug 26 19:50:31 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | DNA damage repair PARP inhibitors Developmental therapeutics Ovarian cancer |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c577t-30f9269b44458f762c811b7bc15f3fecd53e59713832188dc0ac479efd05e69a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0090825819315495 |
| PMID | 31630846 |
| PQID | 2307396204 |
| PQPubID | 23479 |
| PageCount | 10 |
| ParticipantIDs | proquest_miscellaneous_2307396204 pubmed_primary_31630846 crossref_citationtrail_10_1016_j_ygyno_2019_09_021 crossref_primary_10_1016_j_ygyno_2019_09_021 elsevier_sciencedirect_doi_10_1016_j_ygyno_2019_09_021 elsevier_clinicalkeyesjournals_1_s2_0_S0090825819315495 elsevier_clinicalkey_doi_10_1016_j_ygyno_2019_09_021 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-02-01 |
| PublicationDateYYYYMMDD | 2020-02-01 |
| PublicationDate_xml | – month: 02 year: 2020 text: 2020-02-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Gynecologic oncology |
| PublicationTitleAlternate | Gynecol Oncol |
| PublicationYear | 2020 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | S (bib37) 2019; 37 Matulonis (bib42) 2019 Jul 1; 30 Robson (bib2) 2019; 30 Liu (bib34) 2013; 49 Han (bib15) 2018; 29 Gelmon (bib8) 2011; 12 JF (bib36) 2018; 36 Birkbak (bib46) 2013; 8 Pommier, O’Connor, de Bono (bib6) 2016; 8 Das (bib24) 2014; 42 Brill (bib57) 2017; 8 Moore (bib11) 2019; 20 Varga (bib43) 2019; 152 Dean (bib39) 2012; 106 Sun (bib70) 2017; 9 Mateo (bib5) 2015; 373 Bindra (bib29) 2004; 24 Pulliam (bib69) 2018; 24 Ramalingam (bib14) 2017; 23 Oza (bib9) 2017; 147 Shen (bib62) 2007; 128 Armstrong (bib18) 2019; 37 Wahner Hendrickson (bib26) 2018; 24 Matulonis (bib33) 2009; 27 Juvekar (bib60) 2012; 2 Moore (bib1) 2018; 379 J-M, L. (bib52) 2018; 29 Disis (bib44) 2019 Mar 1; 5 Ding (bib48) 2018; 25 Coleman (bib17) 2015; 137 Hamanishi (bib41) 2015; 33 Patel (bib22) 2012; 287 Matulonis (bib63) 2017; 28 Strickland (bib47) 2016; 7 Westin (bib66) 2018; 36 MR (bib40) 2019; 37 Do, Doroshow, Kummar (bib59) 2013; 12 Tahara (bib23) 2014; 13 S (bib65) 2017; 28 LoRusso (bib25) 2016; 22 MR (bib38) 2016; 34 Kim (bib54) 2017; 23 Loibl (bib16) 2018; 19 Konstantinopoulos (bib7) 2015; 5 Golan (bib4) 2019; 381 Shen (bib49) 2019; 79 Y (bib51) 2018; 149 Matulonis (bib12) 2016; 27 Lee (bib56) 2018; 19 Plummer (bib20) 2013; 71 Hjortkjaer (bib27) 2018; 14 Kaplan (bib32) 2019; 11 Yang (bib68) 2017; 9 Lim (bib31) 2014; 16 Bindra (bib30) 2005; 65 TA (bib55) 2016; 69 Martin, Hamilton, Schilder (bib13) 2008; 14 Chalmers (bib21) 2018; 36 Ibrahim (bib61) 2012; 2 Kunos (bib28) 2015; 25 Liu (bib45) 2019 Aug; 154 Yamaguchi (bib67) 2018; 37 Liu (bib35) 2014; 15 Swisher (bib10) 2017; 18 Konstantinopoulos (bib50) 2019 Jun 13 Konstantinopoulos (bib64) 2019; 20 Litton (bib3) 2018; 379 Thaker (bib19) 2017; 28 KT (bib58) 2019; 79 Yazinski (bib53) 2017; 31 Hamanishi (10.1016/j.ygyno.2019.09.021_bib41) 2015; 33 Thaker (10.1016/j.ygyno.2019.09.021_bib19) 2017; 28 Liu (10.1016/j.ygyno.2019.09.021_bib34) 2013; 49 Plummer (10.1016/j.ygyno.2019.09.021_bib20) 2013; 71 Konstantinopoulos (10.1016/j.ygyno.2019.09.021_bib7) 2015; 5 Disis (10.1016/j.ygyno.2019.09.021_bib44) 2019; 5 MR (10.1016/j.ygyno.2019.09.021_bib38) 2016; 34 Oza (10.1016/j.ygyno.2019.09.021_bib9) 2017; 147 Bindra (10.1016/j.ygyno.2019.09.021_bib29) 2004; 24 KT (10.1016/j.ygyno.2019.09.021_bib58) 2019; 79 Matulonis (10.1016/j.ygyno.2019.09.021_bib12) 2016; 27 Liu (10.1016/j.ygyno.2019.09.021_bib35) 2014; 15 Do (10.1016/j.ygyno.2019.09.021_bib59) 2013; 12 Yazinski (10.1016/j.ygyno.2019.09.021_bib53) 2017; 31 Kunos (10.1016/j.ygyno.2019.09.021_bib28) 2015; 25 JF (10.1016/j.ygyno.2019.09.021_bib36) 2018; 36 Matulonis (10.1016/j.ygyno.2019.09.021_bib42) 2019; 30 Lee (10.1016/j.ygyno.2019.09.021_bib56) 2018; 19 Brill (10.1016/j.ygyno.2019.09.021_bib57) 2017; 8 Litton (10.1016/j.ygyno.2019.09.021_bib3) 2018; 379 Ding (10.1016/j.ygyno.2019.09.021_bib48) 2018; 25 Loibl (10.1016/j.ygyno.2019.09.021_bib16) 2018; 19 LoRusso (10.1016/j.ygyno.2019.09.021_bib25) 2016; 22 Hjortkjaer (10.1016/j.ygyno.2019.09.021_bib27) 2018; 14 Armstrong (10.1016/j.ygyno.2019.09.021_bib18) 2019; 37 Konstantinopoulos (10.1016/j.ygyno.2019.09.021_bib50) 2019 Kim (10.1016/j.ygyno.2019.09.021_bib54) 2017; 23 Golan (10.1016/j.ygyno.2019.09.021_bib4) 2019; 381 Yang (10.1016/j.ygyno.2019.09.021_bib68) 2017; 9 Patel (10.1016/j.ygyno.2019.09.021_bib22) 2012; 287 Juvekar (10.1016/j.ygyno.2019.09.021_bib60) 2012; 2 S (10.1016/j.ygyno.2019.09.021_bib65) 2017; 28 Ramalingam (10.1016/j.ygyno.2019.09.021_bib14) 2017; 23 Bindra (10.1016/j.ygyno.2019.09.021_bib30) 2005; 65 Mateo (10.1016/j.ygyno.2019.09.021_bib5) 2015; 373 Das (10.1016/j.ygyno.2019.09.021_bib24) 2014; 42 Dean (10.1016/j.ygyno.2019.09.021_bib39) 2012; 106 Pommier (10.1016/j.ygyno.2019.09.021_bib6) 2016; 8 Yamaguchi (10.1016/j.ygyno.2019.09.021_bib67) 2018; 37 Tahara (10.1016/j.ygyno.2019.09.021_bib23) 2014; 13 Y (10.1016/j.ygyno.2019.09.021_bib51) 2018; 149 Strickland (10.1016/j.ygyno.2019.09.021_bib47) 2016; 7 Varga (10.1016/j.ygyno.2019.09.021_bib43) 2019; 152 Westin (10.1016/j.ygyno.2019.09.021_bib66) 2018; 36 Martin (10.1016/j.ygyno.2019.09.021_bib13) 2008; 14 Shen (10.1016/j.ygyno.2019.09.021_bib49) 2019; 79 Chalmers (10.1016/j.ygyno.2019.09.021_bib21) 2018; 36 S (10.1016/j.ygyno.2019.09.021_bib37) 2019; 37 Swisher (10.1016/j.ygyno.2019.09.021_bib10) 2017; 18 Shen (10.1016/j.ygyno.2019.09.021_bib62) 2007; 128 Lim (10.1016/j.ygyno.2019.09.021_bib31) 2014; 16 Wahner Hendrickson (10.1016/j.ygyno.2019.09.021_bib26) 2018; 24 Moore (10.1016/j.ygyno.2019.09.021_bib11) 2019; 20 MR (10.1016/j.ygyno.2019.09.021_bib40) 2019; 37 Matulonis (10.1016/j.ygyno.2019.09.021_bib63) 2017; 28 Konstantinopoulos (10.1016/j.ygyno.2019.09.021_bib64) 2019; 20 Birkbak (10.1016/j.ygyno.2019.09.021_bib46) 2013; 8 Moore (10.1016/j.ygyno.2019.09.021_bib1) 2018; 379 Ibrahim (10.1016/j.ygyno.2019.09.021_bib61) 2012; 2 Gelmon (10.1016/j.ygyno.2019.09.021_bib8) 2011; 12 Han (10.1016/j.ygyno.2019.09.021_bib15) 2018; 29 Robson (10.1016/j.ygyno.2019.09.021_bib2) 2019; 30 Coleman (10.1016/j.ygyno.2019.09.021_bib17) 2015; 137 Matulonis (10.1016/j.ygyno.2019.09.021_bib33) 2009; 27 Liu (10.1016/j.ygyno.2019.09.021_bib45) 2019; 154 Sun (10.1016/j.ygyno.2019.09.021_bib70) 2017; 9 Kaplan (10.1016/j.ygyno.2019.09.021_bib32) 2019; 11 Pulliam (10.1016/j.ygyno.2019.09.021_bib69) 2018; 24 J-M, L. (10.1016/j.ygyno.2019.09.021_bib52) 2018; 29 TA (10.1016/j.ygyno.2019.09.021_bib55) 2016; 69 |
| References_xml | – volume: 9 year: 2017 ident: bib68 article-title: Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition publication-title: Sci. Transl. Med. – volume: 14 start-page: 1291 year: 2008 end-page: 1295 ident: bib13 article-title: Platinum resistance: the role of DNA repair pathways publication-title: Clin. Cancer Res. – volume: 2 start-page: 1048 year: 2012 end-page: 1063 ident: bib60 article-title: Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer publication-title: Cancer Discov. – volume: 28 start-page: 505 year: 2017 end-page: 511 ident: bib19 article-title: A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852) publication-title: Ann. Oncol. – volume: 20 start-page: 636 year: 2019 end-page: 648 ident: bib11 article-title: Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial publication-title: Lancet Oncol. – volume: 149 start-page: 246 year: 2018 end-page: 247 ident: bib51 article-title: An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): results in germline-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer publication-title: Gynecol. Oncol. – volume: 11 year: 2019 ident: bib32 article-title: Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51 publication-title: Sci. Transl. Med. – volume: 28 year: 2017 ident: bib65 article-title: Phase I expansion of Olaparib (PARP inhibitor) and AZD5363 (AKT inhibitor) in recurrent ovarian, endometrial, and triple negative breast cancer publication-title: Ann. Oncol. – volume: 42 start-page: 4435 year: 2014 end-page: 4449 ident: bib24 article-title: PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage publication-title: Nucleic Acids Res. – volume: 37 year: 2019 ident: bib37 article-title: Evolve: a post PARP inhibitor clinical translational Phase II trial of cediranib-olaparib in ovarian cancer - a Princess Margaret Consortium-GCIG Phase II trial publication-title: J. Clin. Oncol. – volume: 7 start-page: 13587 year: 2016 end-page: 13598 ident: bib47 article-title: Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer publication-title: Oncotarget – volume: 79 year: 2019 ident: bib58 article-title: Phase I combination study of the CHK1 inhibitor Prexasertib (LY2606368) and Olaparib in patients with high-grade serous ovarian cancer and other advanced solids tumors publication-title: Am. Assoc. Canc. Res. – volume: 9 year: 2017 ident: bib70 article-title: Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in publication-title: Sci. Transl. Med. – volume: 287 start-page: 4198 year: 2012 end-page: 4210 ident: bib22 article-title: Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes publication-title: J. Biol. Chem. – volume: 27 start-page: 5601 year: 2009 end-page: 5606 ident: bib33 article-title: Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer publication-title: J. Clin. Oncol. – volume: 30 start-page: 558 year: 2019 end-page: 566 ident: bib2 article-title: OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer publication-title: Ann. Oncol. – volume: 30 start-page: 1080 year: 2019 Jul 1 end-page: 1087 ident: bib42 article-title: Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase 2 KEYNOTE-100 study publication-title: Ann. Oncol. – volume: 24 start-page: 744 year: 2018 end-page: 752 ident: bib26 article-title: A phase I clinical trial of the poly(ADP-ribose) polymerase inhibitor veliparib and weekly topotecan in patients with solid tumors publication-title: Clin. Cancer Res. – year: 2019 Jun 13 ident: bib50 article-title: Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma publication-title: JAMA Oncol. – volume: 65 start-page: 11597 year: 2005 end-page: 11604 ident: bib30 article-title: Hypoxia-induced down-regulation of BRCA1 expression by E2Fs publication-title: Cancer Res. – volume: 5 start-page: 393 year: 2019 Mar 1 end-page: 401 ident: bib44 article-title: Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial publication-title: JAMA Oncol. – volume: 13 start-page: 1170 year: 2014 end-page: 1180 ident: bib23 article-title: The use of Olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks publication-title: Mol. Cancer Ther. – volume: 12 start-page: 3159 year: 2013 end-page: 3164 ident: bib59 article-title: Wee1 kinase as a target for cancer therapy publication-title: Cell Cycle – volume: 5 start-page: 1137 year: 2015 end-page: 1154 ident: bib7 article-title: Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer publication-title: Cancer Discov. – volume: 381 start-page: 317 year: 2019 end-page: 327 ident: bib4 article-title: Maintenance olaparib for germline publication-title: N. Engl. J. Med. – volume: 79 start-page: 311 year: 2019 end-page: 319 ident: bib49 article-title: PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness publication-title: Cancer Res. – volume: 19 start-page: 497 year: 2018 end-page: 509 ident: bib16 article-title: Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial publication-title: Lancet Oncol. – volume: 34 year: 2016 ident: bib38 article-title: A phase 1 study of bevacizumab in combination with niraparib in patients with platinum-sesnstive epithelial ovarian cancer: the ENGOT-OV24/AVANOVA1 trial publication-title: J. Clin. Oncol. – volume: 23 start-page: 1937 year: 2017 end-page: 1944 ident: bib14 article-title: Randomized, placebo-controlled, phase II study of veliparib in combination with carboplatin and paclitaxel for advanced/metastatic non-small cell lung cancer publication-title: Clin. Cancer Res. – volume: 20 start-page: 570 year: 2019 end-page: 580 ident: bib64 article-title: Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial publication-title: Lancet Oncol. – volume: 71 start-page: 1191 year: 2013 end-page: 1199 ident: bib20 article-title: A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation publication-title: Cancer Chemother. Pharmacol. – volume: 15 start-page: 1207 year: 2014 end-page: 1214 ident: bib35 article-title: Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study publication-title: Lancet Oncol. – volume: 2 start-page: 1036 year: 2012 end-page: 1047 ident: bib61 article-title: PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition publication-title: Cancer Discov. – volume: 25 start-page: 484 year: 2015 end-page: 492 ident: bib28 article-title: A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology/Gynecologic Oncology Group study publication-title: Int. J. Gynecol. Cancer – volume: 8 start-page: 362ps17 year: 2016 ident: bib6 article-title: Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action publication-title: Sci. Transl. Med. – volume: 147 start-page: 267 year: 2017 end-page: 275 ident: bib9 article-title: Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2 publication-title: Gynecol. Oncol. – volume: 69 start-page: S2 year: 2016 ident: bib55 article-title: Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination with carboplatin, Olaparib, or durvalumab in patients with advanced cancers publication-title: Eur. J. Cancer – volume: 37 year: 2019 ident: bib18 article-title: A phase I study of Veliparib incorporated into front-line platinum based chemotherapy and Bevacizumab in epithelial ovarian cancer (NCT00989651):a GOG/NRG trial publication-title: J. Clin. Oncol. – volume: 106 start-page: 468 year: 2012 end-page: 474 ident: bib39 article-title: Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours publication-title: Br. J. Canc. – volume: 16 start-page: 343 year: 2014 end-page: 353 ident: bib31 article-title: VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2 publication-title: Neoplasia – volume: 154 start-page: 314 year: 2019 Aug end-page: 322 ident: bib45 article-title: Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers publication-title: Gynecol. Oncol. – volume: 19 start-page: 207 year: 2018 end-page: 215 ident: bib56 article-title: Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study publication-title: Lancet Oncol. – volume: 14 start-page: 7 year: 2018 end-page: 12 ident: bib27 article-title: Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status publication-title: Canc. Treat Res. Commun. – volume: 27 start-page: 1013 year: 2016 end-page: 1019 ident: bib12 article-title: Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety publication-title: Ann. Oncol. – volume: 25 start-page: 2972 year: 2018 end-page: 2980 ident: bib48 article-title: PARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer publication-title: Cell Rep. – volume: 29 start-page: 154 year: 2018 end-page: 161 ident: bib15 article-title: Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study publication-title: Ann. Oncol. – volume: 373 start-page: 1697 year: 2015 end-page: 1708 ident: bib5 article-title: DNA-repair defects and olaparib in metastatic prostate cancer publication-title: N. Engl. J. Med. – volume: 29 year: 2018 ident: bib52 article-title: A phase 2 study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa) publication-title: Ann. Oncol. – volume: 18 start-page: 75 year: 2017 end-page: 87 ident: bib10 article-title: Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial publication-title: Lancet Oncol. – volume: 152 start-page: 243 year: 2019 end-page: 250 ident: bib43 article-title: Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028 publication-title: Gynecol. Oncol. – volume: 49 start-page: 2972 year: 2013 end-page: 2978 ident: bib34 article-title: A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer publication-title: Eur. J. Cancer – volume: 379 start-page: 753 year: 2018 end-page: 763 ident: bib3 article-title: Talazoparib in patients with advanced breast cancer and a germline BRCA mutation publication-title: N. Engl. J. Med. – volume: 12 start-page: 852 year: 2011 end-page: 861 ident: bib8 article-title: Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study publication-title: Lancet Oncol. – volume: 379 start-page: 2495 year: 2018 end-page: 2505 ident: bib1 article-title: Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer publication-title: N. Engl. J. Med. – volume: 36 year: 2018 ident: bib21 article-title: Phase I clinical trials evaluating Olaparib in combination with radiotherapy (RT) adn/or temozolomide (TMZ) in glioblastoma patients: results of OPARATIC and PARADIGM phase I and early results of PARADIGM-2 publication-title: J. Clin. Oncol. – volume: 24 start-page: 8504 year: 2004 end-page: 8518 ident: bib29 article-title: Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells publication-title: Mol. Cell. Biol. – volume: 8 start-page: 111026 year: 2017 end-page: 111040 ident: bib57 article-title: Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases publication-title: Oncotarget – volume: 23 start-page: 3097 year: 2017 end-page: 3108 ident: bib54 article-title: Targeting the ATR/CHK1 Axis with PARP inhibition results in tumor regression in publication-title: Clin. Cancer Res. – volume: 8 year: 2013 ident: bib46 article-title: Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations publication-title: PLoS One – volume: 22 start-page: 3227 year: 2016 end-page: 3237 ident: bib25 article-title: Phase I safety, pharmacokinetic, and pharmacodynamic study of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with irinotecan in patients with advanced solid tumors publication-title: Clin. Cancer Res. – volume: 28 start-page: 512 year: 2017 end-page: 518 ident: bib63 article-title: Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer publication-title: Ann. Oncol. – volume: 24 start-page: 3163 year: 2018 end-page: 3175 ident: bib69 article-title: An effective epigenetic-PARP inhibitor combination therapy for breast and ovarian cancers independent of BRCA mutations publication-title: Clin. Cancer Res. – volume: 31 start-page: 318 year: 2017 end-page: 332 ident: bib53 article-title: ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells publication-title: Genes Dev. – volume: 36 year: 2018 ident: bib66 article-title: Phase I trial of Olaparib (PARP inhibitor) and vistusertib (mTORC1/2 inhibitor) in recurrent endometrial, ovarian, and triple negative breast cancer publication-title: J. Clin. Oncol. – volume: 37 year: 2019 ident: bib40 article-title: Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer. A randomized controlled chemotherapy-free study - NSGO-AVANOVA2/ENGOT-OV24 publication-title: J. Clin. Oncol. – volume: 137 start-page: 386 year: 2015 end-page: 391 ident: bib17 article-title: A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - an NRG Oncology/Gynecologic Oncology Group study publication-title: Gynecol. Oncol. – volume: 36 year: 2018 ident: bib36 article-title: A phase 2 biomarker trial of combination cediranib and Olaparib in relapsed platinum sensitive and platinum resistant ovarian cancer publication-title: J. Clin. Oncol. – volume: 33 start-page: 4015 year: 2015 end-page: 4022 ident: bib41 article-title: Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer publication-title: J. Clin. Oncol. – volume: 128 start-page: 157 year: 2007 end-page: 170 ident: bib62 article-title: Essential role for nuclear PTEN in maintaining chromosomal integrity publication-title: Cell – volume: 37 start-page: 208 year: 2018 end-page: 217 ident: bib67 article-title: EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer publication-title: Oncogene – volume: 27 start-page: 5601 issue: 33 year: 2009 ident: 10.1016/j.ygyno.2019.09.021_bib33 article-title: Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2009.23.2777 – volume: 37 year: 2019 ident: 10.1016/j.ygyno.2019.09.021_bib18 article-title: A phase I study of Veliparib incorporated into front-line platinum based chemotherapy and Bevacizumab in epithelial ovarian cancer (NCT00989651):a GOG/NRG trial publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2019.37.15_suppl.5523 – volume: 29 year: 2018 ident: 10.1016/j.ygyno.2019.09.021_bib52 article-title: A phase 2 study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa) publication-title: Ann. Oncol. – volume: 14 start-page: 7 year: 2018 ident: 10.1016/j.ygyno.2019.09.021_bib27 article-title: Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status publication-title: Canc. Treat Res. Commun. doi: 10.1016/j.ctarc.2017.09.001 – volume: 379 start-page: 753 issue: 8 year: 2018 ident: 10.1016/j.ygyno.2019.09.021_bib3 article-title: Talazoparib in patients with advanced breast cancer and a germline BRCA mutation publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1802905 – volume: 79 issue: 13 year: 2019 ident: 10.1016/j.ygyno.2019.09.021_bib58 article-title: Phase I combination study of the CHK1 inhibitor Prexasertib (LY2606368) and Olaparib in patients with high-grade serous ovarian cancer and other advanced solids tumors publication-title: Am. Assoc. Canc. Res. – volume: 34 year: 2016 ident: 10.1016/j.ygyno.2019.09.021_bib38 article-title: A phase 1 study of bevacizumab in combination with niraparib in patients with platinum-sesnstive epithelial ovarian cancer: the ENGOT-OV24/AVANOVA1 trial publication-title: J. Clin. Oncol. – volume: 37 year: 2019 ident: 10.1016/j.ygyno.2019.09.021_bib40 article-title: Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer. A randomized controlled chemotherapy-free study - NSGO-AVANOVA2/ENGOT-OV24 publication-title: J. Clin. Oncol. – volume: 7 start-page: 13587 issue: 12 year: 2016 ident: 10.1016/j.ygyno.2019.09.021_bib47 article-title: Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer publication-title: Oncotarget doi: 10.18632/oncotarget.7277 – volume: 5 start-page: 393 issue: 3 year: 2019 ident: 10.1016/j.ygyno.2019.09.021_bib44 article-title: Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2018.6258 – volume: 23 start-page: 1937 issue: 8 year: 2017 ident: 10.1016/j.ygyno.2019.09.021_bib14 article-title: Randomized, placebo-controlled, phase II study of veliparib in combination with carboplatin and paclitaxel for advanced/metastatic non-small cell lung cancer publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-15-3069 – volume: 381 start-page: 317 issue: 4 year: 2019 ident: 10.1016/j.ygyno.2019.09.021_bib4 article-title: Maintenance olaparib for germline publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1903387 – volume: 20 start-page: 636 issue: 5 year: 2019 ident: 10.1016/j.ygyno.2019.09.021_bib11 article-title: Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(19)30029-4 – volume: 28 start-page: 512 issue: 3 year: 2017 ident: 10.1016/j.ygyno.2019.09.021_bib63 article-title: Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer publication-title: Ann. Oncol. doi: 10.1093/annonc/mdw672 – volume: 42 start-page: 4435 issue: 7 year: 2014 ident: 10.1016/j.ygyno.2019.09.021_bib24 article-title: PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage publication-title: Nucleic Acids Res. doi: 10.1093/nar/gku088 – volume: 8 start-page: 362ps17 issue: 362 year: 2016 ident: 10.1016/j.ygyno.2019.09.021_bib6 article-title: Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.aaf9246 – volume: 18 start-page: 75 issue: 1 year: 2017 ident: 10.1016/j.ygyno.2019.09.021_bib10 article-title: Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(16)30559-9 – volume: 137 start-page: 386 issue: 3 year: 2015 ident: 10.1016/j.ygyno.2019.09.021_bib17 publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2015.03.042 – volume: 31 start-page: 318 issue: 3 year: 2017 ident: 10.1016/j.ygyno.2019.09.021_bib53 article-title: ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells publication-title: Genes Dev. doi: 10.1101/gad.290957.116 – volume: 19 start-page: 207 issue: 2 year: 2018 ident: 10.1016/j.ygyno.2019.09.021_bib56 article-title: Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(18)30009-3 – volume: 149 start-page: 246 year: 2018 ident: 10.1016/j.ygyno.2019.09.021_bib51 article-title: An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): results in germline-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2018.04.555 – volume: 8 start-page: 111026 issue: 67 year: 2017 ident: 10.1016/j.ygyno.2019.09.021_bib57 article-title: Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases publication-title: Oncotarget doi: 10.18632/oncotarget.22195 – volume: 20 start-page: 570 issue: 4 year: 2019 ident: 10.1016/j.ygyno.2019.09.021_bib64 article-title: Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(18)30905-7 – volume: 24 start-page: 3163 issue: 13 year: 2018 ident: 10.1016/j.ygyno.2019.09.021_bib69 article-title: An effective epigenetic-PARP inhibitor combination therapy for breast and ovarian cancers independent of BRCA mutations publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-18-0204 – volume: 23 start-page: 3097 issue: 12 year: 2017 ident: 10.1016/j.ygyno.2019.09.021_bib54 article-title: Targeting the ATR/CHK1 Axis with PARP inhibition results in tumor regression in publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-16-2273 – volume: 12 start-page: 852 issue: 9 year: 2011 ident: 10.1016/j.ygyno.2019.09.021_bib8 article-title: Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(11)70214-5 – volume: 28 start-page: 505 issue: 3 year: 2017 ident: 10.1016/j.ygyno.2019.09.021_bib19 article-title: A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852) publication-title: Ann. Oncol. doi: 10.1093/annonc/mdw635 – volume: 128 start-page: 157 issue: 1 year: 2007 ident: 10.1016/j.ygyno.2019.09.021_bib62 article-title: Essential role for nuclear PTEN in maintaining chromosomal integrity publication-title: Cell doi: 10.1016/j.cell.2006.11.042 – volume: 36 year: 2018 ident: 10.1016/j.ygyno.2019.09.021_bib36 article-title: A phase 2 biomarker trial of combination cediranib and Olaparib in relapsed platinum sensitive and platinum resistant ovarian cancer publication-title: J. Clin. Oncol. – volume: 16 start-page: 343 issue: 4 year: 2014 ident: 10.1016/j.ygyno.2019.09.021_bib31 article-title: VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2 publication-title: Neoplasia doi: 10.1016/j.neo.2014.04.003 – volume: 69 start-page: S2 year: 2016 ident: 10.1016/j.ygyno.2019.09.021_bib55 article-title: Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination with carboplatin, Olaparib, or durvalumab in patients with advanced cancers publication-title: Eur. J. Cancer doi: 10.1016/S0959-8049(16)32607-7 – volume: 11 issue: 492 year: 2019 ident: 10.1016/j.ygyno.2019.09.021_bib32 article-title: Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51 publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.aav4508 – volume: 9 issue: 392 year: 2017 ident: 10.1016/j.ygyno.2019.09.021_bib70 article-title: Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.aal5148 – volume: 27 start-page: 1013 issue: 6 year: 2016 ident: 10.1016/j.ygyno.2019.09.021_bib12 article-title: Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety publication-title: Ann. Oncol. doi: 10.1093/annonc/mdw133 – volume: 13 start-page: 1170 issue: 5 year: 2014 ident: 10.1016/j.ygyno.2019.09.021_bib23 article-title: The use of Olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-13-0683 – volume: 79 start-page: 311 issue: 2 year: 2019 ident: 10.1016/j.ygyno.2019.09.021_bib49 article-title: PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-18-1003 – volume: 147 start-page: 267 issue: 2 year: 2017 ident: 10.1016/j.ygyno.2019.09.021_bib9 article-title: Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2 publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2017.08.022 – volume: 152 start-page: 243 issue: 2 year: 2019 ident: 10.1016/j.ygyno.2019.09.021_bib43 article-title: Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028 publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2018.11.017 – volume: 30 start-page: 558 issue: 4 year: 2019 ident: 10.1016/j.ygyno.2019.09.021_bib2 article-title: OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer publication-title: Ann. Oncol. doi: 10.1093/annonc/mdz012 – volume: 19 start-page: 497 issue: 4 year: 2018 ident: 10.1016/j.ygyno.2019.09.021_bib16 article-title: Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(18)30111-6 – volume: 287 start-page: 4198 issue: 6 year: 2012 ident: 10.1016/j.ygyno.2019.09.021_bib22 article-title: Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes publication-title: J. Biol. Chem. doi: 10.1074/jbc.M111.296475 – volume: 37 start-page: 208 issue: 2 year: 2018 ident: 10.1016/j.ygyno.2019.09.021_bib67 article-title: EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer publication-title: Oncogene doi: 10.1038/onc.2017.311 – volume: 379 start-page: 2495 issue: 26 year: 2018 ident: 10.1016/j.ygyno.2019.09.021_bib1 article-title: Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1810858 – volume: 373 start-page: 1697 issue: 18 year: 2015 ident: 10.1016/j.ygyno.2019.09.021_bib5 article-title: DNA-repair defects and olaparib in metastatic prostate cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1506859 – volume: 24 start-page: 744 issue: 4 year: 2018 ident: 10.1016/j.ygyno.2019.09.021_bib26 article-title: A phase I clinical trial of the poly(ADP-ribose) polymerase inhibitor veliparib and weekly topotecan in patients with solid tumors publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-17-1590 – volume: 15 start-page: 1207 issue: 11 year: 2014 ident: 10.1016/j.ygyno.2019.09.021_bib35 article-title: Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(14)70391-2 – volume: 30 start-page: 1080 issue: 7 year: 2019 ident: 10.1016/j.ygyno.2019.09.021_bib42 article-title: Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase 2 KEYNOTE-100 study publication-title: Ann. Oncol. doi: 10.1093/annonc/mdz135 – volume: 154 start-page: 314 issue: 2 year: 2019 ident: 10.1016/j.ygyno.2019.09.021_bib45 article-title: Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2019.05.021 – volume: 2 start-page: 1048 issue: 11 year: 2012 ident: 10.1016/j.ygyno.2019.09.021_bib60 article-title: Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-11-0336 – year: 2019 ident: 10.1016/j.ygyno.2019.09.021_bib50 article-title: Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2019.1048 – volume: 36 year: 2018 ident: 10.1016/j.ygyno.2019.09.021_bib66 article-title: Phase I trial of Olaparib (PARP inhibitor) and vistusertib (mTORC1/2 inhibitor) in recurrent endometrial, ovarian, and triple negative breast cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2018.36.15_suppl.5504 – volume: 8 issue: 11 year: 2013 ident: 10.1016/j.ygyno.2019.09.021_bib46 article-title: Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations publication-title: PLoS One doi: 10.1371/journal.pone.0080023 – volume: 49 start-page: 2972 issue: 14 year: 2013 ident: 10.1016/j.ygyno.2019.09.021_bib34 article-title: A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2013.05.020 – volume: 36 year: 2018 ident: 10.1016/j.ygyno.2019.09.021_bib21 article-title: Phase I clinical trials evaluating Olaparib in combination with radiotherapy (RT) adn/or temozolomide (TMZ) in glioblastoma patients: results of OPARATIC and PARADIGM phase I and early results of PARADIGM-2 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2018.36.15_suppl.2018 – volume: 9 issue: 400 year: 2017 ident: 10.1016/j.ygyno.2019.09.021_bib68 article-title: Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.aal1645 – volume: 22 start-page: 3227 issue: 13 year: 2016 ident: 10.1016/j.ygyno.2019.09.021_bib25 article-title: Phase I safety, pharmacokinetic, and pharmacodynamic study of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with irinotecan in patients with advanced solid tumors publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-15-0652 – volume: 106 start-page: 468 issue: 3 year: 2012 ident: 10.1016/j.ygyno.2019.09.021_bib39 article-title: Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours publication-title: Br. J. Canc. doi: 10.1038/bjc.2011.555 – volume: 5 start-page: 1137 issue: 11 year: 2015 ident: 10.1016/j.ygyno.2019.09.021_bib7 article-title: Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-15-0714 – volume: 25 start-page: 2972 issue: 11 year: 2018 ident: 10.1016/j.ygyno.2019.09.021_bib48 article-title: PARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer publication-title: Cell Rep. doi: 10.1016/j.celrep.2018.11.054 – volume: 71 start-page: 1191 issue: 5 year: 2013 ident: 10.1016/j.ygyno.2019.09.021_bib20 article-title: A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation publication-title: Cancer Chemother. Pharmacol. doi: 10.1007/s00280-013-2113-1 – volume: 65 start-page: 11597 issue: 24 year: 2005 ident: 10.1016/j.ygyno.2019.09.021_bib30 article-title: Hypoxia-induced down-regulation of BRCA1 expression by E2Fs publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-05-2119 – volume: 29 start-page: 154 issue: 1 year: 2018 ident: 10.1016/j.ygyno.2019.09.021_bib15 article-title: Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study publication-title: Ann. Oncol. doi: 10.1093/annonc/mdx505 – volume: 12 start-page: 3159 issue: 19 year: 2013 ident: 10.1016/j.ygyno.2019.09.021_bib59 article-title: Wee1 kinase as a target for cancer therapy publication-title: Cell Cycle doi: 10.4161/cc.26062 – volume: 14 start-page: 1291 issue: 5 year: 2008 ident: 10.1016/j.ygyno.2019.09.021_bib13 article-title: Platinum resistance: the role of DNA repair pathways publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-07-2238 – volume: 24 start-page: 8504 issue: 19 year: 2004 ident: 10.1016/j.ygyno.2019.09.021_bib29 article-title: Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells publication-title: Mol. Cell. Biol. doi: 10.1128/MCB.24.19.8504-8518.2004 – volume: 2 start-page: 1036 issue: 11 year: 2012 ident: 10.1016/j.ygyno.2019.09.021_bib61 article-title: PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-11-0348 – volume: 37 year: 2019 ident: 10.1016/j.ygyno.2019.09.021_bib37 article-title: Evolve: a post PARP inhibitor clinical translational Phase II trial of cediranib-olaparib in ovarian cancer - a Princess Margaret Consortium-GCIG Phase II trial publication-title: J. Clin. Oncol. – volume: 25 start-page: 484 issue: 3 year: 2015 ident: 10.1016/j.ygyno.2019.09.021_bib28 article-title: A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology/Gynecologic Oncology Group study publication-title: Int. J. Gynecol. Cancer doi: 10.1097/IGC.0000000000000380 – volume: 33 start-page: 4015 issue: 34 year: 2015 ident: 10.1016/j.ygyno.2019.09.021_bib41 article-title: Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2015.62.3397 – volume: 28 year: 2017 ident: 10.1016/j.ygyno.2019.09.021_bib65 article-title: Phase I expansion of Olaparib (PARP inhibitor) and AZD5363 (AKT inhibitor) in recurrent ovarian, endometrial, and triple negative breast cancer publication-title: Ann. Oncol. |
| SSID | ssj0003012 |
| Score | 2.4899166 |
| SecondaryResourceType | review_article |
| Snippet | PARP inhibitors have transformed the management of advanced high-grade serous ovarian cancer. Despite the overwhelming success of PARP inhibition, particularly... AbstractPARP inhibitors have transformed the management of advanced high-grade serous ovarian cancer. Despite the overwhelming success of PARP inhibition,... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 488 |
| SubjectTerms | Animals Antineoplastic Combined Chemotherapy Protocols - administration & dosage BRCA1 Protein - genetics BRCA2 Protein - genetics Developmental therapeutics DNA damage repair DNA Repair Female Genes, BRCA1 Genes, BRCA2 Germ-Line Mutation Hematology, Oncology, and Palliative Medicine Humans Obstetrics and Gynecology Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Ovarian Neoplasms - immunology PARP inhibitors Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage Randomized Controlled Trials as Topic |
| Title | Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0090825819315495 https://www.clinicalkey.es/playcontent/1-s2.0-S0090825819315495 https://dx.doi.org/10.1016/j.ygyno.2019.09.021 https://www.ncbi.nlm.nih.gov/pubmed/31630846 https://www.proquest.com/docview/2307396204 |
| Volume | 156 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR1ta9Qw-GG7gfhFNl9P3YjgR-uat7bx23k4To-NcTrct9C81FVce1x7yH3ZbzdJ2wPRTRAKgZCHNHlekzwvAK8ZVZmOWR4V1CQRUyKOlCVppHKF80w7lIfs-qdnyeyCfbrklzswHWJhvFtlL_s7mR6kdd9z3O_m8bIsfYyvL9fNnUqjPs8Y34U94rR9NoK9ycf57GwrkB0Nd0nDQ9Q0z4bkQ8HNa_NtU_kgQCxCvlOCb1NQtxmgQRGd7MOD3oJEk-4nD2DHVg_h3mn_Rv4ImulVXfsbAPTTl1LavEOfQ60b33M-WZyjsroqlWPkFXKLdgfj7s4OtTVaBt88i9xul1G7vnZDSh8_YtGqc6W1DVIh5AW9X0wn6HrdPeQ3j-Hi5MOX6SzqSytEmqdpG9G4ECQRijHGs8IJRJ1hrFKlMS9oYbXh1LqjBqa-kFGWGR3nmqXCFibmNhE5fQKjqq7sM0AqSUhhBLPEGMaFUZoVucqYUdhSkZsxkGE_pe7zjvvyFz_k4GD2XQYkSI8EGbuP4DG82QItu7Qbdw9nA6LkEFHqZKB0auFusPRvYLbp-biRWDZExvIPWhtDsoX8jVz_PeWrgY6kY2T_OpNXtl430nvkU-HLA4zhaUdg26VTZzXHzlJ8_r_TvoD7xF8UBHfzlzBqV2t76KypVh3B7tsbfNTzjG_ni6_zXznmIeQ |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIgEXVF5lSwEjcSQ0fiUxt2XVaoFuVZVW6s2KH6FBbbLaZIX2wm_HdpJFqLRISDlZHjn2PDy2v5kBeMuoynTM8qigJomYEnGkLEkjlSucZ9qxPGTXnx0l0zP2-Zyfb8BkiIXxsMre9nc2PVjrvmWvX829eVn6GF9frpu7LY36PGP8DtxlvsyBE-r3P3_jPJwEdynDQ8w0z4bUQwHktfq2qnwIIBYh2ynBN21PN7mfYRs62IKHvf-Ixt0vPoINWz2Ge7P-hfwJNJOLuvbnf_TDF1JafUBfQ6Ub33I8PjlGZXVRKqfGC-Sm7I7F3Y0dams0D8g8i9xal1G7vHJdSh89YtGiA9LaBqkQ8II-nkzG6GrZPeM3T-HsYP90Mo36wgqR5mnaRjQuBEmEYozxrHDmUGcYq1RpzAtaWG04te6ggakvY5RlRse5ZqmwhYm5TUROn8FmVVf2OSCVJKQwglliDOPCKM2KXGXMKGypyM0IyLCeUvdZx33xi0s5wMu-y8AE6ZkgY_cRPIJ3a6J5l3Tj9u5sYJQc4kmdBZRuU7idLP0bmW16LW4klg2RsbwmaSNI1pR_COu_h3wzyJF0auzfZvLK1stGejw-Fb44wAi2OwFbT506nzl2fuLO_w77Gu5PT2eH8vDT0ZcX8ID4K4MAPN-FzXaxtC-dX9WqV0FvfgGNtiED |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Choosing+wisely%3A+Selecting+PARP+inhibitor+combinations+to+promote+anti-tumor+immune+responses+beyond+BRCA+mutations&rft.jtitle=Gynecologic+oncology&rft.au=Veneris%2C+Jennifer+Taylor&rft.au=Matulonis%2C+Ursula+A&rft.au=Liu%2C+Joyce+F&rft.au=Konstantinopoulos%2C+Panagiotis+A&rft.date=2020-02-01&rft.issn=0090-8258&rft_id=info:doi/10.1016%2Fj.ygyno.2019.09.021&rft.externalDBID=ECK1-s2.0-S0090825819315495&rft.externalDocID=1_s2_0_S0090825819315495 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0090-8258&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0090-8258&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0090-8258&client=summon |